Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spectranetics Catheter Sales Benefiting From RotaLink Recall

This article was originally published in The Gray Sheet

Executive Summary

Spectranetics placed 16 atherectomy lasers and saw sales of disposable coronary angioplasty catheters more than double in the third quarter, largely at the expense of Boston Scientific's RotaLink Plus atherectomy system, the company reported Nov. 30 at the BancBoston Robertson Stephens annual health care conference in New York City.

You may also be interested in...



Boston Scientific's Rotablator Anticipated To Generate $15 mil. In Q4 Sales

A limited reintroduction of Boston Scientific's original Rotablator rotational atherectomy device later this month is anticipated to generate $15 mil. in sales for the firm in the fourth quarter.

Baxter v. Spectranetics

Patent infringement suit is filed by Baxter in Delaware district court alleging that Spectranetics' CVX-300 excimer laser system infringes three patents licensed by Baxter from Lasersight (patent number 4,784,135), Acculase (4,891,818), and the U.S. Department of Energy/Argonne National Laboratory (4,686,979). The patents cover cardiovascular and vascular uses of excimer laser technology. Spectranetics' CVX-300 is approved for laser angioplasty in coronary arteries. The company also is planning trials in October to use the system to treat in-stent restenosis

Boston Scientific Pursues Dual Strategy In Addressing RotaLink Recall

Boston Scientific may opt to restart production of its original Rotablator atherectomy system following the Aug. 6 recall of the next-generation RotaLink Plus, the company reported at a same-day teleconference.

Related Content

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel